Anokion
30 articles about Anokion
-
Anokion to Participate in BofA Healthcare Trailblazers Conference
10/19/2023
Anokion SA announced today that Deborah Geraghty, Ph.D., president and chief executive officer, will participate in the BofA Healthcare Trailblazers Private Company Conference on Thursday, October 26, 2023, in Boston, Mass.
-
Anokion Announces Nature Biomedical Engineering Publication Further Validating its Immune Tolerance Approach to Treating Celiac Disease and Multiple Sclerosis
9/19/2023
Anokion Announces Nature Biomedical Engineering Publication Further Validating its Immune Tolerance Approach to Treating Celiac Disease and Multiple Sclerosis.
-
Anokion Announces Clinical Progress with KAN-101 and ANK-700
9/12/2023
Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today reported progress for its clinical-stage programs, KAN-101 and ANK-700. The company’s lead product candidate, KAN-101, is being evaluated for the treatment of celiac disease, and its second candidate, ANK-700, is being evaluated for the treatment of multiple sclerosis (MS).
-
Anokion Strengthens its Senior Leadership with Promotions and New Appointment
9/7/2023
Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, announced a series of senior leadership promotions and a new senior appointment, effective immediately.
-
Anokion Announces Publication in The Lancet Gastroenterology & Hepatology Highlighting Safety and Preliminary Effects of KAN-101 in Celiac Disease in its ACeD Phase 1 Clinical Trial
6/15/2023
Anokion SA announced that The Lancet Gastroenterology & Hepatology has published clinical data on KAN-101 from the Phase 1 ACeD Trial, which support the favorable safety of KAN-101 and signals of dose-dependent reactivity to gluten and induction of immune tolerance in patients with celiac disease.
-
Anokion Announces New Clinical Data from the Phase 1 ACeD Trial Supporting KAN-101 as a Potential Disease-modifying Treatment for Celiac Disease
5/9/2023
Anokion SA today announced favorable new pharmacodynamic and pharmacokinetic data from the company’s completed Phase 1 clinical trial evaluating KAN-101 as a treatment for celiac disease.
-
Anokion Announces Leadership Team Expansion to Support Advancement of Clinical-Stage Autoimmune Pipeline
10/27/2022
Anokion SA , a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced appointments to the company’s leadership team to support the continued advancement of its pipeline, including its clinical-stage programs, KAN-101 and ANK-700.
-
Anokion Announces Presentation of Data from Phase 1 ACeD Clinical Trial Evaluating KAN-101 as a Treatment for Celiac Disease at the 19th International Celiac Disease Symposium
10/21/2022
Anokion Announces Presentation of Data from Phase 1 ACeD Clinical Trial Evaluating KAN-101 as a Treatment for Celiac Disease at the 19th International Celiac Disease Symposium.
-
Anokion Announces $35 Million Equity Investment from Pfizer
10/18/2022
Anokion SA , a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that Pfizer has made a $35 million equity investment in Anokion through the Pfizer Breakthrough Growth Initiative.
-
A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
-
Anokion Announces Positive Data from Phase 1 ACeD Clinical Trial Evaluating KAN-101 as a Treatment for Celiac Disease Presented in a Plenary Session at DDW 2022
5/23/2022
Anokion SA announced positive clinical trial results from the company’s Phase 1 ACeD (Assessment of KAN-101 in Celiac Disease) clinical trial evaluating its lead candidate, KAN-101.
-
Anokion Announces Progress Across Pipeline of Novel Autoimmune Programs
1/6/2022
Anokion SA today reported progress for its clinical-stage programs, KAN-101 and ANK-700.
-
Anokion Initiates Patient Dosing in Phase 1 Trial of ANK-700 for the Treatment of Multiple Sclerosis
3/23/2021
Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced the initiation of patient dosing in its Phase 1 clinical trial to evaluate ANK-700 for the treatment of people with relapsing remitting multiple sclerosis (RRMS).
-
Anokion Announces Initiation of Multiple-Ascending Dose Portion of its Phase 1 Clinical Trial with KAN-101 for the Treatment of Celiac Disease
3/16/2021
Anokion SA , a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that the company has initiated patient dosing in the multiple ascending dose (MAD) portion of its ACeD study
-
Anokion Announces Publication in Science Immunology
3/1/2021
Anokion SA , a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced the publication of data highlighting the company’s original erythrocyte binding technology in Science Immunology
-
Many drug makers are investing in new science and hope to develop new therapeutics that address autoimmune disease. BioSpace has captured some key efforts.
-
Anokion Announces Expansion of Exclusive Collaboration with Bristol Myers Squibb to Develop Novel Treatments for Autoimmune Diseases
9/22/2020
Global, Multi-Program Collaboration Now Includes Anokion’s Novel Product Candidates for Celiac Disease, in addition to Multiple Sclerosis and the Platform CAMBRIDGE, Mass. & LAUSANNE, Switzerland--( BUSINESS WIRE )-- Anokion SA , a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced the expansion of an exclusive global collaboration agreement with Bristol Myers Squibb, focused
-
Anokion to Participate in Jefferies 2020 Virtual Healthcare Conference
5/26/2020
Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, announced that management will participate in the Jefferies 2020 Virtual Healthcare Conference being held from June 2-4, 2020.
-
Anokion Announces Initiation of Patient Dosing in Phase 1 Clinical Trial of KAN-101 in Celiac Disease
2/27/2020
Anokion SA today announced the initiation of patient dosing in the company’s multi-center Phase 1 clinical trial to evaluate KAN-101, the company’s lead antigen-specific drug candidate, for the treatment of celiac disease.
-
Anokion to Present at the 3rd Antigen Specific Immune Tolerance Summit
2/19/2020
Feb. 19, 2020 13:30 UTC Anokion to Present at the 3 rd Antigen Specific Immune Tolerance Summit CAMBRIDGE, Mass. & LAUSANNE, Switzerland--( BUSINESS WIRE )-- Anokion SA , a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that Stephan Kontos, Ph.D., co-founder and chief scientific officer of Anokion, will give a presentation titled, “Translational & Clinical Development of Novel, Liver Targeted Immune